NovoCure Limited
NVCR
$17.96
$0.070.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 621.71M | 605.22M | 577.74M | 549.96M | 525.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 621.71M | 605.22M | 577.74M | 549.96M | 525.66M |
| Cost of Revenue | 141.06M | 136.23M | 135.53M | 132.25M | 131.61M |
| Gross Profit | 480.65M | 468.99M | 442.21M | 417.72M | 394.05M |
| SG&A Expenses | 434.74M | 428.92M | 383.76M | 383.68M | 388.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 787.63M | 774.79M | 729.96M | 728.34M | 733.09M |
| Operating Income | -165.91M | -169.57M | -152.22M | -178.37M | -207.43M |
| Income Before Tax | -129.82M | -131.16M | -114.49M | -141.13M | -172.30M |
| Income Tax Expenses | 34.37M | 37.47M | 35.29M | 27.57M | 20.44M |
| Earnings from Continuing Operations | -164.19 | -168.63 | -149.78 | -168.70 | -192.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -164.19M | -168.63M | -149.78M | -168.70M | -192.74M |
| EBIT | -165.91M | -169.57M | -152.22M | -178.37M | -207.43M |
| EBITDA | -155.54M | -159.70M | -142.64M | -168.45M | -197.64M |
| EPS Basic | -1.51 | -1.56 | -1.39 | -1.57 | -1.81 |
| Normalized Basic EPS | -0.90 | -0.92 | -0.79 | -0.95 | -1.12 |
| EPS Diluted | -1.51 | -1.56 | -1.39 | -1.57 | -1.81 |
| Normalized Diluted EPS | -0.90 | -0.92 | -0.79 | -0.95 | -1.12 |
| Average Basic Shares Outstanding | 434.70M | 431.69M | 430.20M | 428.72M | 427.31M |
| Average Diluted Shares Outstanding | 434.70M | 431.69M | 430.20M | 428.72M | 427.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |